Agenus BOT+BAL meets primary endpoint in Phase 2 MSS colon cancer trial
Bitget2026/11/02 11:43- Agenus announced published Phase 2 UNICORN results in Nature Medicine evaluating preoperative botensilimab plus balstilimab in resectable, locally advanced colon cancer.
- The combination produced deep tumor responses, including complete tumor clearance in some patients with microsatellite-stable disease, which historically resisted conventional immunotherapy.
- No combination-treated patients experienced cancer recurrence by the February 9, 2026, data cutoff; all trial participants underwent surgery.
- The findings support the planned randomized Phase 3 ROBBIN trial comparing the combination followed by standard care against standard care alone.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
